11
total announcements
543960.BO · 15 min delayed
Concord Biotech Ltd
Concord Biotech Ltd has informed that its officials will be attending an investor conference on August 26, 2026, in Ahmedabad.
Concord Biotech Ltd
Concord Biotech Ltd reported a strong start to FY27 with Q1 FY27 revenues of INR257 crores, reflecting a 26% year-on-year growth. The company encountered challenges in FY26 but remains confident of sustaining momentum in FY27 due to its long-term growth strategy, niche capabilities, and leadership position in key molecules.
Concord Biotech Ltd
Concord Biotech Ltd has hosted the audio recording of its Q1 FY27 earnings call on its website.
Concord Biotech Ltd
Concord Biotech Ltd has released its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, showing a broad-based growth across all product categories, with exports growing by ~46% for Q1FY27 (Y-o-Y). The company has also witnessed an increase in wallet share among existing customers, addition of new products, and a robust product pipeline. The financial highlights include a revenue growth of +26%, EBITDA growth of +34%, and PAT growth of +31%.
Concord Biotech Ltd
Concord Biotech Ltd has announced the voting results of its 41st Annual General Meeting (AGM), where all resolutions were passed with requisite majority. The company has declared a dividend and appointed a new director.
Concord Biotech Ltd
Concord Biotech Ltd has published unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, with revenue and profit details provided.
Concord Biotech Ltd
Concord Biotech Ltd held its 41st Annual General Meeting on July 31, 2026, through video conferencing. The meeting was attended by 38 members, and the requisite quorum was present. The Chairman and Managing Director, Mr. Sudhir Vaid, addressed the shareholders and gave an overview of the company's operations and financial performance for the year ended March 31, 2026. The meeting was conducted in accordance with the provisions of the Companies Act, 2013, and the Statutory Auditors' Report and the Secretarial Audit Report did not contain any qualification, reservation, adverse remark, or disclaimer.
Concord Biotech Ltd
Concord Biotech Ltd has announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The results were approved by the Board of Directors, and a Limited Review Report was issued by M/s. BSR & Co. LLP, the Statutory Auditors. The report highlights that the company's financial results are in compliance with Indian Accounting Standard 34 and other accounting principles generally accepted in India.
Concord Biotech Ltd
Concord Biotech Ltd has announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, with the Board of Directors approving the results at its meeting held on July 31, 2026.
Concord Biotech Ltd
Concord Biotech Ltd has arranged an earnings call to discuss its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, scheduled on August 3, 2026.
Concord Biotech Ltd
Concord Biotech Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 to consider and approve the unaudited Standalone and Consolidated Financial Results for the first quarter ended on June 30, 2026 along with Limited Review Report thereon.